Cramer: Buying Trea...
Health Care: Drugs
Enzon Pharmaceuticals Inc. (ENZN: NASDAQ)
$6.41 -0.02 | -0.31%
06/01/12 - 04:00 PM ET
Ratio Comparisons
| Company | Industry | S&P 500 | |
| Valuation Ratios | |||
|---|---|---|---|
| P/E Ratio (TTM) | n.a. | 75.30 | 17.70 |
| P/E High - Last 5 Yrs | n.a. | n.a. | 67.70 |
| P/E Low - Last 5 Yrs | n.a. | n.a. | 12.50 |
| Beta | 1.15 | 0.58 | 0.98 |
| Price to Sales (TTM) | 7.62 | 4.62 | 1.42 |
| Price to Book (MRQ) | 1.57 | 3.44 | 2.41 |
| Price to Tangible Book (MRQ) | 1.57 | 6.74 | 5.08 |
| Price to Cash Flow (TTM) | -18.50 | 26.10 | 9.80 |
| Price to Free Cash Flow (TTM) | -20.90 | 48.80 | 17.40 |
| Dividends | |||
| Dividend Yield (%) | 0.00 | 0.50 | 2.10 |
| Dividend Yield - 5 Yr Avg (%) | n.a. | 0.20 | 2.20 |
| Dividend 5 Yr Growth Rate (%) | n.a. | n.a. | -0.76 |
| Payout Ratio (TTM) | 0.00 | 3.00 | 30.00 |
| Sales (MRQ) vs Qtr 1 Yr Ago (%) | -41.20 | 9.90 | 11.80 |
| Sales (TTM) vs TTM 1 Yr Ago (%) | -50.90 | 7.70 | 9.20 |
| Growth Rates (%) | |||
| Sales - 5 Yr Growth Rate (%) | -23.89 | 9.03 | 1.79 |
| EPS (MRQ) vs Qtr 1 Yr Ago (%) | -100.00 | 18.50 | 17.50 |
| EPS (TTM) vs TTM 1 Yr Ago (%) | -100.00 | 18.50 | 17.50 |
| EPS - 5 Yr Growth Rate (%) | n.a. | n.a. | -1.66 |
| Capital Spending - 5 Yr Growth Rate (%) | n.a. | -4.13 | -1.17 |
| Financial Strength | |||
| Quick Ratio (MRQ) | 9.60 | 2.90 | 1.10 |
| Current Ratio (MRQ) | 9.80 | 3.50 | 1.60 |
| LT Debt to Equity (MRQ) | 0.64 | 0.41 | 0.82 |
| Total Debt to Equity (MRQ) | 0.64 | 0.45 | 0.96 |
| Interest Coverage (TTM) | n.a. | 6.20 | 5.50 |
| Profitability Ratios (%) | |||
| Gross Margin (TTM) | n.a. | 84.10 | 46.90 |
| Gross Margin - 5 Yr Avg | 86.80 | 83.50 | 47.70 |
| EBITD Margin (TTM) | -16.00 | 27.30 | 18.90 |
| EBITD - 5 Yr Avg | 22.43 | 0.00 | 0.00 |
| Pre-Tax Margin (TTM) | -54.30 | 14.10 | 12.10 |
| Pre-Tax Margin - 5 Yr Avg | 8.00 | 10.60 | 10.30 |
| Management Effectiveness (%) | |||
| Net Profit Margin (TTM) | -0.55 | 0.10 | 0.09 |
| Net Profit Margin - 5 Yr Avg | 33.30 | 5.30 | 7.00 |
| Return on Assets (TTM) | -6.60 | 4.70 | 3.10 |
| Return on Assets - 5 Yr Avg | 12.30 | 2.20 | 2.50 |
| Return on Investment (TTM) | -6.90 | 6.10 | 7.90 |
| Return on Investment - 5 Yr Avg | 13.80 | 2.80 | 6.50 |
| Efficiency | |||
| Revenue/Employee (TTM) | 564,597.00 | 701,747.00 | 449,376.00 |
| Net Income/Employee (TTM) | -309,236.00 | 83,589.00 | 39,003.00 |
| Receivable Turnover (TTM) | n.a. | 5.80 | 7.60 |
| Inventory Turnover (TTM) | n.a. | 1.30 | 8.30 |
| Asset Turnover (TTM) | 0.10 | 0.40 | 0.40 |
Portfolios with ENZN
- Portfolio NameUser Type
- ProSeth Klarman - Baupost Group
- ProCarl Icahn
- UserGFNN Stockdiagnostics 12
- UserVermonty #1
- ProRichard Perry - Perry Capital
- ProMichael Price - MFP Investors
- UserInternational Value Fund
- UserRichard_stocks
- ContributorBarron's Activist Stocks 5-...
- UserASCO 2010 Part 2
Latest ENZN Headlines from TheStreet
- Enzon Pharmaceuticals Inc. (ENZN): Today's Featured Drugs Loser 10.05.11 | 04:10 pm
- Enzon Stock Hits New 52-Week Low (ENZN) 09.30.11 | 03:09 pm
- Enzon Stock Hits New 52-Week Low (ENZN) 09.22.11 | 02:09 pm
- Enzon Pharmaceuticals Inc. Stock Downgraded (ENZN) 08.09.11 | 07:08 am
- Enzon Stock Hits New 52-Week Low (ENZN) 08.04.11 | 11:08 am
- Enzon Stock Hits New 52-Week Low (ENZN) 07.27.11 | 10:07 am
- Enzon Stock Hits New 52-Week Low (ENZN) 06.17.11 | 04:06 pm
- 2 New Stock Picks From Baupost's Klarman 05.16.11 | 06:05 am
- Carl Icahn Bets Big on 23 Stocks 02.16.11 | 06:02 am
- Enzon Pharmaceuticals, Inc. Q1 2010 Earnings Call Transcript 05.10.10 | 11:05 pm
Press Releases for ENZN
- Enzon Announces Reduction In Force To Align Operations With Research And Development Activities - Business Wire 09.22.11 | 04:09 pm
- ENZON Names Ana I. Stancic Chief Financial Officer - Business Wire 05.31.11 | 06:05 am
- Enzon Announces Discontinuation Of PEG-SN38 Program In Metastatic Colorectal Carcinoma In Light Of Evolving Standards Of Care - Business Wire 05.19.11 | 06:05 am
- Enzon Reports 1st Quarter 2011 Results - Business Wire 05.06.11 | 08:05 am
- Enzon Presents Data At 2011 AACR Meeting - Business Wire 04.05.11 | 04:04 pm
- Enzon Appoints Richard Mulligan, Ph.D. Vice-Chairman Of The Board; Adopts Majority Vote Standard For Election Of Directors - Business Wire 03.17.11 | 04:03 pm
- Enzon Reports 2010 Results - Business Wire 02.17.11 | 04:02 pm
- Enzon To Release Fourth Quarter 2010 Earnings On Thursday, February 17, 2011; Conference Call And Webcast To Follow - Business Wire 02.10.11 | 07:02 am
- Enzon To Begin Phase 1 Study Of Novel Androgen Receptor MRNA Antagonist In Castration-Resistant Prostate Cancer - Business Wire 01.10.11 | 07:01 am
- Enzon Board Authorizes Share Repurchase Program - Business Wire 12.21.10 | 04:12 pm
Partner Headlines for ENZN
- 5 Biotech Stocks That Could Double - Seeking Alpha 02.01.12 | 07:02 am
- Billionaire Carl Icahn's Top Stock Picks And Portfolio Activity - Seeking Alpha 11.23.11 | 08:11 am
- Tracking Seth Klarman's Baupost Group Holdings - Seeking Alpha 10.18.11 | 09:10 am
- 11 Stocks Carl Icahn And Jim Simons Are Bullish On - Seeking Alpha 09.18.11 | 09:09 am
- 10 Profitable, Small Cap Stocks With Strong Growth And Bullish Trends - Seeking Alpha 08.22.11 | 08:08 am
- Weak Top Line Widens Enzon Loss - Analyst Blog - Zacks 08.09.11 | 10:08 am
- Weak Top Line Widens Enzon Loss - Analyst Blog - Zacks 08.09.11 | 10:08 am
- Seth Klarman's Favorite Stock Picks - Seeking Alpha 07.26.11 | 09:07 am
- Enzon Pharmaceuticals (ENZN) - Bear of the Day - Zacks 06.15.11 | 01:06 am
- Enzon Pharmaceuticals (ENZN) - Bear of the Day - Zacks 06.07.11 | 01:06 am
